All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bispecific Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 14, 2020
Details:
Boehringer Ingelheim will use OBT’s OGAP® platform to identify novel target opportunities for new immunotherapies utilizing their T-cell engager, cancer vaccine and oncolytic virus platforms.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Takara Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 12, 2020
Details:
PanCELLa agreement marks Merck’s first CRISPR license for bioproduction . Takara Bio USA agreement gives access to Merck’s CRISPR integration and vector technologies for Takara’s vector products and cell engineering services.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IgM antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: IGM Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 24, 2020
Details:
AbCellera will generate panels of antibodies for multiple therapeutic targets identified by IGM using its full-stack and IGM will have the rights to develop and commercialize the novel antibodies resulting from this collaboration.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bispecific Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: REMD
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 16, 2020
Details:
In the collaboration, GenScript ProBio allowed REMD to use its SMAB bispecific antibody platform to develop novel cancer immunotherapy drugs. GenScript ProBio will support REMD with the selection and development of bispecific antibody candidates.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Mono- and Bispecific human antibodies
Therapeutic Area: Oncology Product Name: OmniAb
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: Ligand Pharmaceuticals
Deal Size: $5.0 million Upfront Cash: $5.0 million
Deal Type: Acquisition September 10, 2020
Details:
The acquisitions are expected to enable Ligand to secure new license agreements with expanded economics as a result of the addition of tools and intellectual property that Ligand can now offer to partners.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Mono- and Bispecific human antibodies
Therapeutic Area: Oncology Product Name: OmniAb
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: Ligand Pharmaceuticals
Deal Size: $7.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 10, 2020
Details:
The acquisition will strengthen company's OmniAb® technology platform. Potential for two approvals of OmniAb-derived antibodies in 2021 with expected new royalty streams to Ligand.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Small molecule
Partner/Sponsor/Collaborator: Exscientia
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 09, 2020
Details:
Under this collaboration, Exscientia will use its advanced Centaur Chemist AI platform to design new molecules against project specific targets and Huadong will apply its experimental and managerial capabilities to support Exscientia’s AI design in a rapid closed-loop cycle.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Chinese Hamster Ovary K1 cell
Therapeutic Area: Oncology Product Name: Chosource
Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: TrueBinding
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 29, 2020
Details:
TrueBinding will use Horizon’s cGMP-compliant CHOSOURCE™ platform for the development and commercialization of multiple biotherapeutic products for applications in immuno-oncology and other disease areas with great unmet medical need.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $85.0 million Upfront Cash: Undisclosed
Deal Type: Financing July 29, 2020
Details:
Financing proceeds support identification of novel therapeutic targets and enable genomic medicine programs across a wide range of therapeutic areas
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): T-cell therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: JW Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 20, 2020
Details:
JW Therapeutics has acquired Syracuse Biopharma, which includes the license for Eureka Therapeutics’ ARTEMIS® antibody TCR and solid tumor technology for exclusive use in China and the ASEAN countries.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
